Immunomodulatory and pharmacologic properties of imiquimod - 11/05/12
Abstract |
Imiquimod, an imidazoquinoline amine, is an immune response modifier recently approved for the topical treatment of external genital and perianal warts. Although the majority of immunomodulatory agents available or in development inhibit pathways involved in immune activation, imiquimod is unique in that it activates immune function. The exact mechanism of imiquimod’s antiviral activity is unknown; however, its effects are likely to be related to its immunomodulating properties. Although in vitro studies have shown that imiquimod has no direct antiviral effects, the drug does exhibit antiviral and antitumor effects in vivo through induction of cytokines and enhancement of cell-mediated cytolytic antiviral activity. Imiquimod stimulates the innate immune response through induction of cytokines, and the cellular arm of acquired immunity through induction of interferon-⍺ (IFN-⍺), IFN-γ, and interleukin-12. Results from animal studies have indicated a possible use for imiquimod in the prevention and treatment of herpes simplex virus infection. In addition, recent studies demonstrated that imiquimod activates Langerhans’ cells and enhances allergic contact hypersensitivity. (J Am Acad Dermatol 2000;43:S6-11.)
Le texte complet de cet article est disponible en PDF.Plan
Daniel N. Sauder, MD, has worked as a paid consultant for 3M. |
|
Reprint requests: Daniel N. Sauder, MD, FRCP, FACP, Division of Dermatology, University of Toronto, 2975 Bayview Ave, M1-734 Toronto, Ontario, Canada M4N 3M5. |
Vol 43 - N° 1P2
P. S6-S11 - juillet 2000 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?